HomeCompareIMRNW vs CL

IMRNW vs CL: Dividend Comparison 2026

IMRNW yields 2339.18% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMRNW wins by $43075570633.31M in total portfolio value
10 years
IMRNW
IMRNW
● Live price
2339.18%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43075570633.35M
Annual income
$39,734,102,642,272,360.00
Full IMRNW calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — IMRNW vs CL

📍 IMRNW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMRNWCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMRNW + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMRNW pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMRNW
Annual income on $10K today (after 15% tax)
$198,830.41/yr
After 10yr DRIP, annual income (after tax)
$33,773,987,245,931,504.00/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, IMRNW beats the other by $33,773,987,245,926,910.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMRNW + CL for your $10,000?

IMRNW: 50%CL: 50%
100% CL50/50100% IMRNW
Portfolio after 10yr
$21537785316.70M
Annual income
$19,867,051,321,138,880.00/yr
Blended yield
92.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

IMRNW
No analyst data
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMRNW buys
0
CL buys
0
No recent congressional trades found for IMRNW or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMRNWCL
Forward yield2339.18%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$43075570633.35M$40.8K
Annual income after 10y$39,734,102,642,272,360.00$5,401.96
Total dividends collected$42841070616.16M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IMRNW vs CL ($10,000, DRIP)

YearIMRNW PortfolioIMRNW Income/yrCL PortfolioCL Income/yrGap
1← crossover$244,618$233,918.13$11,012$312.01+$233.6KIMRNW
2$5,609,462$5,347,721.02$12,196$412.95+$5.60MIMRNW
3$120,610,820$114,608,695.17$13,599$549.66+$120.60MIMRNW
4$2,432,079,455$2,303,025,877.36$15,288$736.64+$2432.06MIMRNW
5$46,004,003,878$43,401,678,861.20$17,353$995.28+$46003.99MIMRNW
6$816,480,868,143$767,256,583,993.93$19,926$1,357.80+$816480.85MIMRNW
7$13,600,083,122,647$12,726,448,593,733.79$23,194$1,873.82+$13600083.10MIMRNW
8$212,667,837,578,363$198,115,748,637,130.90$27,439$2,621.52+$212667837.55MIMRNW
9$3,122,867,281,384,664$2,895,312,695,175,815.50$33,088$3,727.38+$3122867281.35MIMRNW
10$43,075,570,633,353,950$39,734,102,642,272,360.00$40,806$5,401.96+$43075570633.31MIMRNW

IMRNW vs CL: Complete Analysis 2026

IMRNWStock

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers’ diarrhea in the United States, and Travelers’ Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Full IMRNW Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this IMRNW vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMRNW vs SCHDIMRNW vs JEPIIMRNW vs OIMRNW vs KOIMRNW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.